Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Alzheimer's
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Alzheimer's
    Hypertension, Markers of Inflammation In the Blood More Common in Offspring of Parents With AD - (DGNews)
    TopAbstracts in Alzheimer's 10/29/2009 - (DGNews)
    Diabetes Does Not Increase Rate of Cognitive Decline in Patients With AD - (DGNews)
    Half of Patients With Alzheimer's Disease Adhere to Cholinesterase Inhibitors After 1 Year: Presented at ANA - (DGDispatch)
    TopAbstracts in Alzheimer's 10/15/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Alzheimer's
    The Dementia Caregiver-A Primary Care Approach
    Medical Care of the Patient with Dementia

    Webcasts/CME archive

     Recent cases - Alzheimer's
      Rapid Cognitive Improvement in Alzheimer's Disease Following Perispinal Etanercept Administration
      Advances in the Pharmacotherapy of Alzheimer's Disease
      Does He Have Alzheimer's Disease?

      Cases archive
        




      my personal edition > alzheimer's > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Galantamine Hydrobromide Delays Alzheimer's Symptoms by 18 Months: Presented at APA

      By Alison Palkhivala

      PHILADELPHIA, PA -- May 23, 2002 -- The anti-dementia drug galantamine hydrobromide has been shown to delay the cognitive decline of Alzheimer's disease over three years, according to new research.

      The study was presented here this week at the annual meeting of the American Psychiatric Association (APA).

      For this three-year analysis, Alzheimer's disease patients, who were involved in one of two earlier double-blind trials comparing galantamine hydrobromide to placebo, were asked if they would like to participate in further research. They were given the opportunity to continue the drug (24 mg/day) as part of an open-label design.

      A total of 327 patients entered the open-label trial; 182 completed the study, 90 took galantamine hydrobromide continuously for 36 months.

      The investigators, led by Murray Raskind, MD, director of the Alzheimer's Disease Research Center at the department of Veteran's Affairs, Puget Sound Healthcare System, in Tacoma, Washington, assessed the cognition of the participants at 12, 24, and 36 months and compared it to expected rates of cognitive decline in untreated patients. Expected rates of decline were based on research by Robert Stern, MD, from the University of Massachusetts. The ADAS-cog/11 scale was used to assess cognition.

      According to a post-hoc analysis, after three years, 53 percent of patients on galantamine hydrobromide declined by 10 points or less on the ADAS-cog/11 scale. This is half the cognitive decline expected in untreated Alzheimer's patients over the same time period.

      One-fifth of the galantamine hydrobromide patients had not declined significantly below their baseline values. The investigators estimate that galantamine hydrobromide delays progression of Alzheimer's disease by approximately 18 months.`



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send